Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Brody JD, Jorgensen J, Belada D, Costello R, et al. Blood 2025;145:1621-1631.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Brody JD, Jorgensen J, Belada D, Costello R, et al. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood 2025;145:1621-1631.
PMID: 39792928